about
Recent developments and innovations in gastric cancerThe efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials.Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer.Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer.A case report of trastuzumab dose in gastric cancer.Strategies for gastric cancer in the modern era.Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.Non-curative gastric resection for patients with stage 4 gastric cancer--a single center experience and current review of literature.Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain.Trastuzumab in HER2-positive metastatic gastric cancer: profile report.Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers
P2860
Q26751327-F7FD3F19-682F-4A7B-B95A-C736C86248BCQ33437413-0B6E5D07-A989-46B5-905E-C04B90160037Q33799233-4803ADDD-2171-4F2B-9CDF-A9793CF05494Q35998729-2C408BD1-F9EA-4609-807A-7BB18CB66A86Q36770491-2F281596-7998-4BE7-AF96-5E3ECF60EBF1Q37092749-A00878D8-4EA5-4C7B-B010-7EBE6BC1A580Q37285942-2D71BA6A-C6C4-43B8-8DF3-CDA7341C9D3DQ37821266-77A8BF3C-AC3B-421A-B5AF-8BE6097139CDQ37824265-4D19403F-2B1C-473B-8AE9-83A3C7303651Q37981607-FAE7629F-AFC9-4E4D-95D2-A845ACCF3C14Q38134835-372E8BD9-81BE-41A8-84B6-8E99D4EE629DQ38868199-F9354EF2-A3A9-4F32-A68C-3F5676FCB87AQ39528185-30452959-B088-4F7E-BE4F-4DF43C0BDF70Q42066502-B0FE9776-1709-4421-A982-22D650BD8B11Q54569855-6AE276DF-663F-4AA2-A5CD-FCEA50BDD8FAQ56441338-54F0E29F-75B6-4A53-B7FA-DB1FE7B2D0C2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trastuzumab for gastric cancer.
@en
Trastuzumab for gastric cancer.
@nl
type
label
Trastuzumab for gastric cancer.
@en
Trastuzumab for gastric cancer.
@nl
prefLabel
Trastuzumab for gastric cancer.
@en
Trastuzumab for gastric cancer.
@nl
P2093
P2860
P1476
Trastuzumab for gastric cancer.
@en
P2093
Heather-Jane Au
Judith Meza-Junco
Michael B Sawyer
P2860
P304
P356
10.1517/14712590903439702
P407
P577
2009-12-01T00:00:00Z